Brind.

MSK is accelerating BriaCell's immunotherapy development by providing GMP manufacturing and regulatory support.

1 report, 1 independent Updated Aug 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Memorial Sloan Kettering Cancer Center

Keep exploring

The entities involved

Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
- MoU signed between Memorial Sloan Kettering Cancer Center and a Ministry of Public Health for a new cancer treatment hospital.Wed 22:30

Coverage

Newest first; wire copies grouped

Aug 13GlobeNewswireBriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.